Subscribe
shutterstock_1653845269_taljat_david
Taljat David / Shutterstock.com
30 September 2021Big PharmaTom Phillips

Novartis sues Chinese firm over attempts to make generic heart failure drug

Pharma giant Novartis has filed a patent suit against Crystal Pharmaceuticals after the rival sought to create a generic version of its heart failure drug Entresto (sacubitril/valsartan).

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Biotechnology
Novartis told to pay $178m over infringing cancer drug
26 July 2021   A California jury has ordered Novartis to pay $178 million to rival drugmaker Daiichi Sankyo for willfully infringing two cancer drug patents.
Big Pharma
UKIPO rejects Novartis’s TM opposition attempt
18 June 2020   Switzerland-based Novartis has failed to convince the UK Intellectual Property Office that a trademark applied-for by Boston Healthcare should not be registered.


Editor's picks

Europe
UPC confirms validity of Edwards Lifesciences heart valve tech patent
23 July 2024

Editor's picks

Europe
UPC confirms validity of Edwards Lifesciences heart valve tech patent
23 July 2024
Americas
New-look WIPR Leaders 2024 is ‘most rigorous’ yet
2 July 2024
Americas
Earthquake Chevron: A massive shock to the system?
2 July 2024
Americas
Amarin wins appeal to advance ‘skinny label’ suit over Hikma generic
27 June 2024
Biotechnology
Guardant Health files suit against Tempus AI
13 June 2024
Big Pharma
Roche fires lawsuit at Sinocare unit over blood glucose test strip patents
6 June 2024

More on this story

Biotechnology
Novartis told to pay $178m over infringing cancer drug
26 July 2021   A California jury has ordered Novartis to pay $178 million to rival drugmaker Daiichi Sankyo for willfully infringing two cancer drug patents.
Big Pharma
UKIPO rejects Novartis’s TM opposition attempt
18 June 2020   Switzerland-based Novartis has failed to convince the UK Intellectual Property Office that a trademark applied-for by Boston Healthcare should not be registered.

More on this story

Biotechnology
Novartis told to pay $178m over infringing cancer drug
26 July 2021   A California jury has ordered Novartis to pay $178 million to rival drugmaker Daiichi Sankyo for willfully infringing two cancer drug patents.
Big Pharma
UKIPO rejects Novartis’s TM opposition attempt
18 June 2020   Switzerland-based Novartis has failed to convince the UK Intellectual Property Office that a trademark applied-for by Boston Healthcare should not be registered.

More features

Chinese biotech takes out US rival’s nucleic acid patent at PTAB
Lewis Roca promotes tech expert to managing partner
Panitch Schwarze brings in molecular biologist
US targets ‘product hopping’ with biologic litigation curbs
UPC confirms validity of Edwards Lifesciences heart valve tech patent
ITC concludes row over biotech lab equipment between US and German rivals
UKIPO launches ‘revolutionary’ patent filing and AI tool
USPTO clarifies AI's role in patent eligibility